Sysnav Healthcare and Roche are entering into a partnership to facilitate the development of industry-standard outcome measurements in diseases associated with movement impairments, as well as designing the next generation of wearable technology.
The companies have expanded their collaboration across multiple programs to develop meaningful digital endpoints that will monitor disease progression, support clinical trials and serve as regulatory-approved standards of outcome measurement.
The partnership will also develop the next-generation wearable technology to further promote personalised healthcare.
Patients living with a neuromuscular disorder often suffer from movement impairments that fundamentally impact their daily life. Reliable, objective measurements of a patient's change in motor function can help doctors prescribe the most appropriate therapy and support research aimed to develop new medicines which improve lives.
Sysnav Healthcare has developed medical-grade wearables based on magneto-inertial technology for 3D movement reconstruction. This enables precise movement tracking without GPS, thus protecting patient privacy while enabling indoor monitoring.
Sysnav has already secured the first-ever qualification of a digital endpoint (SV95c) with the European Medicines Agency for Duchenne's Muscular Dystrophy, having worked closely with academic collaborators, patients associations and Roche.
Join the HealthXL Meeting on ‘Product Differentiation for Digital Health Solutions in the Cardiometabolic Disease Area’ on 7th February. Click here to Request to Join.
Click here to read the original news story.